GlaxoSmithKline PLC (GSK) was built on Tuesday by a pharmaceutical company based on the success of previous long-acting treatments, so Shionogi in Japan to use it in a regimen with a dosing gap of 3 months or more. Announced that it will develop HIV treatment by Yoshi Pharmaceutical.
The UK company said it would pay Shionogi £ 20 million ($ 27.36 million) in advance and an additional £ 15 million ($ 20.3 million) upon completion of the S-365598 therapy development milestone, and human testing by 2023. Added that is planned.
GSK’s ViiV Healthcare Unit, with a small investment by Shionogi and Pfizer, will work with a Japanese pharmaceutical company to provide experimental treatment to prevent HIV virus replication by blocking the enzymes released by the HIV virus. ..
“We will continue this collaboration [with Shionogi] We will explore the potential of the S-365598 to secure the ViiV Healthcare pipeline after 2030, “said Kimberly Smith, Head of R & D at the GSK Unit.
Gilead Sciences’ Tolvada daily oral pills are currently the standard of care to prevent HIV infection, but GSK focuses on shorter, longer-lasting regimens and lower-dose, less toxic alternatives. I would like to challenge its superiority by guessing.
According to the World Health Organization, about 1.5 million new HIV infections were reported worldwide in 2020, and about 38 million lived with HIV at the end of last year.
GSK’s ViiV has also developed a long-acting HIV-injected cavenuba that uses cabotegravir in combination with Janssen’s rilpivirine, and another combination of dolutegravir and lamivudine.
Earlier this year, rival Gilead worked with Merck to test an experimental HIV drug combination as a long-acting treatment for the AIDS-causing virus.